Journal: Frontiers in Immunology
Article Title: Engineering HER2-targeted biparatopic antibodies to promote receptor internalization and restore antitumor efficacy
doi: 10.3389/fimmu.2025.1711433
Figure Lengend Snippet: A9B5-Bs-5 and A9B5-Bs-7 inhibit the growth of trastuzumab-resistant HER2-positive cancer cells. (A, B) Growth inhibition in NCI-N87 (A) and BT474 cells (B) treated with bpAbs in the absence of ligands, measured by CCK-8 assay. (C, D) Growth inhibition in NCI-N87 (C) and BT474 cells (D) treated with bpAbs in the presence of EGF or HRG, measured by CCK-8 assay. Serum-starved cells were incubated with anti-HER2 diluted antibodies in the presence of 1 nM HRG or 5 nM EGF. Horizontal dotted line (black) represents viability of non-treated cells referenced to 100%. Data represent mean ± SD (n = 3). (E) Heat map of EC 50 values (nM) derived from CCK-8 assays showing dose-dependent inhibition by bpAbs. Source data are available in the Source Data file.
Article Snippet: For ligand-dependent assays, tumor cells were stimulated with either 1 nM HRG (SinoBiological, 11609-HNCH) or 5 nM EGF (SinoBiological, GMP-10605-HNAE).
Techniques: Inhibition, CCK-8 Assay, Incubation, Derivative Assay